#22

its still too early (only mice…) but read that :

" Since chronic rapamycin treatment also leads to glucose intolerance in mice, we performed a glucose tolerance test on a separate cohort of 24-month-old male mice subjected to KU0063794 for 2 months. KU0063794 did not affect glucose tolerance in old mice as there was no difference in glucose clearance dynamics between the control and treated groups"

and we know rapamycin, both in mice and human impair glucose tolerance

1 Like
#23

Yes, they also need to test lipid levels (mice don’t die of cardiovascular issues so a high lipid level may kill humans but not mice), and immune system function. But yes, those results with the glucose tolerance test sounds promising.

I think the most promising compound right now is the new mTOR1 selective inhibitors from Tornado Therapeutics. See more here: Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging

和：Joan Mannick, Translating Aging Podcast: “Taking disease by sTORm”: Developing Rapalogs to Extend Healthy Lifespan"

#24

Yes. When I first started rapamycin I freaked out a little because my lipids and glucose were well in range. and then spiked when I started rapamycin.

I found out over time that things like berberine, bempadoic, acid, etc., brought back everything into a good range. The other things that have a very significant effect on glucose and lipids of course are diet and exercise.

1 Like